Category - Developments

Developments

Cassava Sciences PTI-125 fails Phase 2b Alzheimer’s disease study

Cassava Sciences (NASDAQ:SAVA) reported disappointing topline results from its Phase 2b study of PTI-125 for the treatment of Alzheimer’s disease (AD). The study enrolled 64 patients with mild-to-moderate AD, 50-to-85...

May 15, 2020

Developments

Capricor reports positive topline data from Phase 2 DMD trial

Capricor Therapeutics (NASDAQ:CAPR) reported positive topline 12-month results of its Phase 2 clinical trial of CAP-1002 for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002-treated patients demonstrated...

May 13, 2020

Developments

AVROBIO updates data on gene therapy trials for Fabry disease, cystinosis

AVROBIO (NASDAQ:AVRO) updated data on its Phase 2 and Phase 1/2 trials evaluating its lentiviral-based gene therapies for the treatment of Fabry disease and cystinosis, respectively. Fabry disease is a genetic disease...

May 13, 2020

Developments

Gamida Cell reports positive topline data from Phase 3 omidubicel trial

Gamida Cell (NASDAQ:GMDA) reported positive topline results from its Phase 3 study of omidubicel in patients with high-risk hematologic malignancies undergoing a bone marrow transplant. The study achieved its primary...

May 12, 2020

Developments

CytoSorbents gets EU approval for CytoSorb

The European Union approved CytoSorbents‘ (NASDAQ:CTSO) CytoSorb blood purification technology for the removal of rivaroxaban during cardiothoracic surgery requiring cardiopulmonary bypass. Rivaroxaban is a...

May 12, 2020

Developments

Helius’ PoNS treatment gets FDA breakthrough designation for MS

Helius Medical Technologies’ (NASDAQ:HSDT; TSX:HSM) portable neuromodulation stimulator (PoNS) received FDA breakthrough designation for the treatment of gait deficit due to symptoms of multiple sclerosis (MS). The non...

May 12, 2020

Developments

PharmAust achieves successful Phase 2 cancer study in pet dogs

PharmAust (ASX:PAA) achieved a successful outcome in a Phase 2 trial investigating the anti-cancer effects of its monepantel tablets in dogs with treatment naïve B-cell lymphoma. Following 14 days of monepantel tablet...

May 12, 2020

Developments

Imagin Medical supports Bladder Cancer Awareness Month

This month, Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) will be undertaking a number of efforts and activities to help raise awareness about bladder cancer. Imagin has created and will...

May 12, 2020

Developments

Kane Biotech posts positive results from anti-biofilm shampoo consumer product test

Kane Biotech (TSX-V:KNE) reported positive results from its consumer product test evaluating the efficacy of its new shampoo on dermatitis and dandruff. The shampoo was developed based on research indicating that...

May 12, 2020

Developments

Kiniksa Pharma updates data from COVID-19, chronic pruritis studies

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported updated data from its open-label study of mavrilimab for the treatment of COVID-19-related pneumonia, as well as its Phase 2 trial for vixarelimab for the treatment of...

May 11, 2020

Category - Developments

Cassava Sciences PTI-125 fails Phase 2b Alzheimer’s disease study

Capricor reports positive topline data from Phase 2 DMD trial

AVROBIO updates data on gene therapy trials for Fabry disease, cystinosis

Gamida Cell reports positive topline data from Phase 3 omidubicel trial

CytoSorbents gets EU approval for CytoSorb

Helius’ PoNS treatment gets FDA breakthrough designation for MS

PharmAust achieves successful Phase 2 cancer study in pet dogs

Imagin Medical supports Bladder Cancer Awareness Month

Kane Biotech posts positive results from anti-biofilm shampoo consumer product test

Kiniksa Pharma updates data from COVID-19, chronic pruritis studies

General

More